{
  "1": "ClinicalTrials.gov shows only one completed interventional study for gout that (1) began in May 2006, (2) was conducted in the United States, and (3) listed either pegloticase or placebo as a main intervention.\n\n• NCT00325195 – “Efficacy and Safety Study of Pegloticase (Puricase®) in Patients With Chronic Gout Refractory to Conventional Treatment”  \n  – Design: Phase 3, multicentre, randomized, double-blind, placebo-controlled  \n  – Interventions: Pegloticase 8 mg every 2 weeks, Pegloticase 8 mg every 4 weeks, or placebo  \n  – Study start: 17 May 2006 (first patient / study-start month recorded as May 2006)  \n  – Location: 67 U.S. sites  \n  – Status: Completed (primary completion May 2007; study completion June 2007)\n\nNo other completed U.S. gout trials that started in May 2006 list pegloticase or placebo as their primary intervention(s).",
  "2": "The PubMed ID (PMID) is 40483449.",
  "3": "The PubMed ID (PMID) is 40366360.",
  "4": "OpenTargets lists the following tractability “hits” for IGF1R (Ensembl ID ENSG00000140443) where the tractability assessment is True.\n\nSmall-molecule (SM) modality\n• Approved Drug  \n• Structure with Ligand  \n• High-Quality Ligand  \n• High-Quality Pocket  \n• Druggable Family  \n\nAntibody (AB) modality\n• Approved Drug  \n• UniProt sub-cellular location – high confidence  \n• Gene Ontology cellular-component – high confidence  \n• UniProt signal peptide or TMHMM (secreted / trans-membrane)  \n\nPROTAC / targeted degradation (PR) modality\n• Literature evidence  \n• UniProt ubiquitination annotation  \n• Database ubiquitination annotation  \n• Half-life data available  \n• Known small-molecule binder  \n\nOther modalities / oligonucleotide & cell therapy (OC)\n• Approved Drug",
  "5": "The unique PubMed identifier (PMID) for that article is 39958333.",
  "6": "OpenTargets lists the following diseases for the target ERBB2 (Ensembl ID ENSG00000141736) with a relevance score ≥ 0.5:\n\n• Non-small-cell lung carcinoma (EFO_0003060) – score ≈ 0.76  \n• Cancer, broad term (MONDO_0004992) – 0.73  \n• Breast carcinoma (EFO_0000305) – 0.70  \n• Neoplasm, broad term (EFO_0000616) – 0.68  \n• Gastric cancer (MONDO_0001056) – 0.67  \n• Breast adenocarcinoma (EFO_0000304) – 0.64  \n• Breast cancer (MONDO_0007254) – 0.63  \n• Lung adenocarcinoma (EFO_0000571) – 0.62  \n• Urinary bladder carcinoma (MONDO_0004986) – 0.61  \n• Breast neoplasm (EFO_0003869) – 0.61  \n• Lung cancer (MONDO_0008903) – 0.60  \n• HER2-positive breast carcinoma (EFO_1000294) – 0.58  \n• Gastric adenocarcinoma (EFO_0000503) – 0.56  \n• Glomerular filtration rate (EFO_0005208) – 0.56  \n• Urinary bladder cancer (MONDO_0001187) – 0.54  \n• Ovarian cancer (MONDO_0008170) – 0.53",
  "7": "The PubMed identifier (PMID) for that article is 40311855.",
  "8": "OpenTargets lists the following tractability evidence for TLR9 (ENSG00000239732) with value = True:\n\n• Modality: SM (small-molecule)  \n  – Approved Drug  \n  – High-Quality Ligand  \n  – Druggable Family  \n\n• Modality: AB (antibody/biologic)  \n  – GO Cellular-Component (high confidence)  \n  – UniProt Signal Peptide or TMHMM annotation  \n\n• Modality: PR (protein/peptide or proteolysis-based)  \n  – Database Ubiquitination  \n  – Small-Molecule Binder  \n\n• Modality: OC (other clinical)  \n  – Advanced Clinical",
  "9": "OpenTargets lists the following diseases that are associated with VEGFA (ENSG00000112715) with a relevance score ≥ 0.5:\n\n1. Diabetic retinopathy (EFO_0003770) – score ≈ 0.69  \n2. Age-related macular degeneration (EFO_0001365) – score ≈ 0.67  \n3. Wet macular degeneration (EFO_0004683) – score ≈ 0.65  \n4. Macular retinal edema (MONDO_0003005) – score ≈ 0.61  \n5. Non-small cell lung carcinoma (EFO_0003060) – score ≈ 0.61  \n6. Breast cancer (MONDO_0007254) – score ≈ 0.61  \n7. Glioblastoma multiforme (EFO_0000519) – score ≈ 0.60  \n8. Neoplasm (EFO_0000616) – score ≈ 0.59  \n9. Ovarian cancer (MONDO_0008170) – score ≈ 0.58  \n10. Renal cell carcinoma (EFO_0000681) – score ≈ 0.57  \n11. Macular degeneration (EFO_0009606) – score ≈ 0.56  \n12. Ocular vascular disease (EFO_0005753) – score ≈ 0.55  \n13. Hematocrit (EFO_0004348) – score ≈ 0.55  \n14. Colorectal neoplasm (EFO_0004142) – score ≈ 0.55  \n15. Hemoglobin measurement (EFO_0004509) – score ≈ 0.54  \n16. Colorectal adenocarcinoma (EFO_0000365) – score ≈ 0.54  \n17. Erythrocyte count (EFO_0004305) – score ≈ 0.53  \n18. Cervical cancer (MONDO_0002974) – score ≈ 0.53  \n19. Neutrophil count (EFO_0004833) – score ≈ 0.52  \n20. Platelet count (EFO_0004309) – score ≈ 0.52  \n21. Leukocyte count (EFO_0004308) – score ≈ 0.52  \n22. HbA1c measurement (EFO_0004541) – score ≈ 0.51  \n23. Ovarian carcinoma (EFO_0001075) – score ≈ 0.50  \n24. Macrovascular complications of diabetes (EFO_0010977) – score ≈ 0.50",
  "10": "The PubMed ID (PMID) for that 2025 Neurogastroenterology & Motility article is 40145420.",
  "11": "The PubMed ID (PMID) for that article is 40050163.",
  "12": "The PubMed ID (PMID) for that article is 40434450.",
  "13": "The PubMed identifier (PMID) for that article is 40483090.",
  "15": "The unique PubMed identifier (PMID) for that article is 40122575.",
  "18": "The PMID is 40320805.",
  "19": "ClinicalTrials.gov shows only one study that matches all of the requested criteria (interventional, Non-Hodgkin Lymphoma, lenalidomide, study start in August 2005, United States, and overall status = Completed):\n\n• NCT00179660  \n  Title (original): “Phase II Study of Lenalidomide (CC-5013) in Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma”  \n  Study type: Interventional (single-arm, Phase II)  \n  Start date: August 2005  \n  Primary country of conduct: United States  \n  Overall status: Completed\n\nNo other completed interventional lenalidomide trials for Non-Hodgkin’s Lymphoma list an August 2005 U.S. start date.",
  "20": "The PubMed identifier (PMID) for that article is 40306462.",
  "22": "OpenTargets safety data for the target MTOR (mechanistic target of rapamycin) and the safety event “heart disease” show:\n\n• Biosample(s) in which an association between MTOR perturbation and the event was observed  \n  – Cardiovascular system (UBERON_0004535)\n\n• No specific molecular- or phenotypic-effect annotations were returned (effects = null).\n\nIn other words, MTOR has a recorded safety signal for “heart disease,” mapped to the cardiovascular system biosample, but there are no detailed effect descriptors in the current dataset.",
  "23": "OpenTargets lists the following diseases associated with ADRB1 (ENSG00000043591) with an evidence score ≥ 0.5:\n\n1. Hypertension (EFO_0000537)\n2. Cardiovascular disease (EFO_0000319)\n3. Myocardial infarction (EFO_0000612)\n4. Open-angle glaucoma (EFO_0004190)\n5. Glaucoma (MONDO_0005041)\n6. Heart failure (EFO_0003144)\n7. Angina pectoris (EFO_0003913)\n8. Ocular hypertension (EFO_1001069)\n9. Migraine disorder (MONDO_0005277)\n10. Congestive heart failure (EFO_0000373)\n11. Asthma (MONDO_0004979)\n12. Sudden cardiac arrest (EFO_0004278)\n13. Ventricular arrhythmia (HP_0004308)\n14. Sepsis (HP_0100806)\n15. Pain (EFO_0003843)\n16. Sinusitis (EFO_0007486)\n17. Hypotension (EFO_0005251)\n18. Stroke (EFO_0000712)\n19. High-density lipoprotein cholesterol measurement (EFO_0004612)\n20. Septic shock (EFO_0006834)\n21. Systolic blood pressure (EFO_0006335)\n22. Triglyceride measurement (EFO_0004530)\n23. Atrial fibrillation (EFO_0000275)\n24. Allergic disease (MONDO_0005271)\n25. Diastolic blood pressure (EFO_0006336)\n\nAll have OpenTargets association scores of 0.55–0.74 (≥ 0.5).",
  "24": "ClinicalTrials.gov lists two interventional U.S. studies that specifically:\n\n• enrolled subjects with Type 2 Diabetes Mellitus  \n• used exenatide (long-acting‐release, once-weekly formulation) as an intervention  \n• had a study start date that fell within April 2006  \n\n1. NCT00308139 – “Safety and Efficacy Study of Exenatide Long-Acting Release (Once-Weekly) to Treat Type 2 Diabetes”  \n   • Phase 3, randomized, double-blind, placebo-controlled  \n   • First participant/Study start: 12 April 2006  \n   • United States sites only  \n   • Compared once-weekly exenatide LAR with placebo in patients not adequately controlled on metformin\n\n2. NCT00313001 – “Safety and Efficacy of Exenatide Long-Acting Release in Subjects With Type 2 Diabetes Mellitus”  \n   • Phase 3, randomized, open-label  \n   • First participant/Study start: 26 April 2006  \n   • United States sites only  \n   • Compared once-weekly exenatide LAR with twice-daily immediate-release exenatide\n\nNo other interventional trials on ClinicalTrials.gov meet all four criteria (T2DM condition, exenatide or exenatide LAR intervention, April 2006 start, and U.S. location).",
  "25": "OpenTargets reports the following diseases / traits that meet or exceed a relevance score of 0.5 for the target ENSG00000015413 (DPEP1):\n\n1. Infection (EFO_0000544) – score ≈ 0.579  \n2. Urinary tract infection (EFO_0003103) – score ≈ 0.572  \n3. Body height (EFO_0004339) – score ≈ 0.569  \n4. Sepsis (HP_0100806) – score ≈ 0.566  \n5. Pneumonia (EFO_0003106) – score ≈ 0.565  \n6. Diastolic blood pressure (EFO_0006336) – score ≈ 0.563  \n7. Endocarditis (EFO_0000465) – score ≈ 0.559  \n8. Cysteinylglycine measurement (EFO_0800133) – score ≈ 0.557  \n9. Cys-Gly, oxidized measurement (EFO_0800122) – score ≈ 0.553  \n10. Cysteinylglycine disulfide measurement (EFO_0800049) – score ≈ 0.545  \n11. Osteoarthritis (MONDO_0005178) – score ≈ 0.522",
  "27": "The PubMed identifier (PMID) for that article is 40153166.",
  "28": "The PubMed ID (PMID) for that article is 40358755.",
  "29": "OpenTargets lists the following diseases with an overall association score ≥ 0.5 for the target MTOR (Ensembl ID ENSG00000198793):\n\n1. Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome (EFO_0009050) – score ≈ 0.83\n2. Isolated focal cortical dysplasia type II (MONDO_0011818) – score ≈ 0.82\n3. Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR-pathway genes (MONDO_0100283) – score ≈ 0.65\n4. Neurodegenerative disease (EFO_0005772) – score ≈ 0.56\n5. Clear cell renal carcinoma (EFO_0000349) – score ≈ 0.54\n6. CEBALID syndrome (MONDO_0032908) – score ≈ 0.52",
  "31": "OpenTargets associates IL-13 (Ensembl ID ENSG00000169194) with the following diseases at a relevance score ≥ 0.5:\n\n• Atopic eczema (EFO_0000274) – score ≈ 0.70  \n• Asthma (MONDO_0004979) – score ≈ 0.68  \n• Eczematoid dermatitis (HP_0000964) – score ≈ 0.61  \n• Allergic rhinitis (EFO_0005854) – score ≈ 0.57  \n• Psoriasis (EFO_0000676) – score ≈ 0.55",
  "33": "OpenTargets lists two diseases that reach or exceed the requested 0.5 relevance-score threshold for the target ANGPT1 (Ensembl ID ENSG00000154188):\n\n1. Open-angle glaucoma (EFO_0004190) – score ≈ 0.548  \n2. Intraocular pressure measurement (EFO_0004695) – score ≈ 0.513",
  "34": "The PubMed ID (PMID) is 40445929.",
  "36": "ClinicalTrials.gov shows only one interventional U.S. study that meets all the stated criteria (condition = Clostridium Infection or Diarrhea, drug = PAR-101/OPT-80 or Vancomycin, study start month = October 2006, country = United States):\n\nNCT00384527  \nTitle: “A Study to Determine the Safety and Efficacy of OPT-80 (PAR-101, fidaxomicin) Versus Vancomycin for the Treatment of Clostridium difficile–Associated Diarrhea (CDAD)”  \n• Condition(s): Clostridium difficile Infection / Diarrhea  \n• Interventions: OPT-80 (fidaxomicin / PAR-101) vs. Vancomycin  \n• Study type: Phase 3, randomized, double-blind, active-controlled, interventional  \n• Study start: October 2006  \n• Locations: United States sites only (multi-center)\n\nNo other interventional trials in the ClinicalTrials.gov database began in October 2006 in the United States with those drugs and conditions.",
  "37": "OpenTargets lists the following diseases/phenotypes that are associated with the target GABRA2 (Ensembl ID ENSG00000151834) with an evidence score ≥ 0.5:\n\n• Alcohol dependence (MONDO_0007079) – score ≈ 0.68  \n• Epilepsy (EFO_0000474) – score ≈ 0.61  \n• Major depressive disorder (MONDO_0002009) – score ≈ 0.61  \n• Insomnia (EFO_0004698) – score ≈ 0.61  \n• Panic disorder (EFO_0004262) – score ≈ 0.60  \n• Agitation (HP_0000713) – score ≈ 0.60  \n• Anxiety disorder (EFO_0006788) – score ≈ 0.60  \n• Anxiety (EFO_0005230) – score ≈ 0.60  \n• Migraine disorder (MONDO_0005277) – score ≈ 0.60  \n• Seizure (HP_0001250) – score ≈ 0.59  \n• Pain (EFO_0003843) – score ≈ 0.58  \n• Depressive disorder (MONDO_0002050) – score ≈ 0.57  \n• Generalized anxiety disorder (EFO_1001892) – score ≈ 0.56  \n• Postpartum depression (EFO_0007453) – score ≈ 0.56  \n• Lennox-Gastaut syndrome (MONDO_0016532) – score ≈ 0.55  \n• Status epilepticus (EFO_0008526) – score ≈ 0.55  \n• Developmental and epileptic encephalopathy (MONDO_0100062) – score ≈ 0.54  \n• Stiff-Person syndrome (EFO_0007498) – score ≈ 0.53",
  "38": "The unique PubMed ID (PMID) for that article is 40167622.",
  "39": "ClinicalTrials.gov lists one interventional study that matches all of the requested criteria (Relapsing-Remitting Multiple Sclerosis, BG00012 as the main intervention, study start month = January 2007, and United States sites):\n\n• NCT00420212 – “Efficacy and Safety Study of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)”\n  – Study type: Interventional, randomized, double-blind, placebo-controlled  \n  – Phase: II  \n  – Start date: January 2007  \n  – Sponsor: Biogen  \n  – Intervention: BG00012 (dimethyl fumarate) oral capsules at multiple dose levels  \n  – Locations: United States and other countries\n\nNo other BG00012 interventional trials for RRMS have a listed start date in January 2007 in the U.S.",
  "40": "For the target TUBB (Ensembl ID ENSG00000196230), OpenTargets lists the following tractability opportunities with value = True:\n\nSmall-molecule tractability (SM)\n• Approved Drug  \n• Structure with Ligand  \n• High-Quality Ligand  \n• Druggable Family  \n\nAntibody tractability (AB)\n• GO Cellular-Component (high confidence)\n\nPROTAC / targeted-protein–removal tractability (PR)\n• UniProt Ubiquitination evidence  \n• Database Ubiquitination evidence  \n• Half-life Data available  \n• Known Small-Molecule Binder  \n\nOther/compound modality (OC)\n• Approved Drug",
  "41": "Completed U.S.–based interventional trials in ClinicalTrials.gov that:\n\n• list “Type 2 Diabetes Mellitus” as a studied condition  \n• use the intervention “Exenatide Once Weekly” (long-acting exenatide, e.g., Bydureon, ITCA 650, etc.)  \n• have an overall study status of “Completed”\n\nare the following 28 studies:\n\n1. NCT00103935  \n2. NCT00308139  \n3. NCT00637273  \n4. NCT00641056  \n5. NCT00676338  \n6. NCT00717457  \n7. NCT00753896  \n8. NCT00803920  \n9. NCT00806520  \n10. NCT00877890  \n11. NCT00894322  \n12. NCT01064687  \n13. NCT01104701  \n14. NCT01144338  \n15. NCT01554618  \n16. NCT01652716  \n17. NCT01652729  \n18. NCT01885208  \n19. NCT02119819  \n20. NCT02229383  \n21. NCT02229396  \n22. NCT02251431  \n23. NCT02288273  \n24. NCT02843399  \n25. NCT02917057  \n26. NCT02974244  \n27. NCT02981069  \n28. NCT03970044\n\nThese are all interventional studies whose record indicates they were conducted (at least in part) in the United States, are completed, and involved once-weekly exenatide in people with type 2 diabetes.",
  "42": "The PubMed ID (PMID) is 40360142.",
  "43": "Only one interventional carfilzomib trial for multiple myeloma fits all of the requested criteria (completed status, U.S. sites, and study start in August 2007):\n\n• NCT00530816 – “Phase 2, Multicenter, Open-Label Study of Single-Agent Carfilzomib (PX-171-003) in Patients With Relapsed and/or Refractory Multiple Myeloma.”  \n  • Study type: Interventional  \n  • Study start date: August 2007  \n  • Recruitment status: Completed  \n  • Study locations: United States (multicenter)\n\nNo other completed interventional carfilzomib studies for multiple myeloma initiated in August 2007 were registered on ClinicalTrials.gov.",
  "44": "OpenTargets currently links TYMS (ENSG00000176890) to the following disease entities with an overall association score ≥ 0.5:\n\n1. Dyskeratosis congenita, digenic – score ≈ 0.66  (MONDO_0031057)  \n2. Breast cancer – score ≈ 0.62  (MONDO_0007254)  \n3. Neoplasm (generic) – score ≈ 0.61  (EFO_0000616)  \n4. Dyskeratosis congenita – score ≈ 0.60  (MONDO_0015780)  \n5. Non-small-cell lung carcinoma – score ≈ 0.59  (EFO_0003060)  \n6. Breast carcinoma – score ≈ 0.58  (EFO_0000305)  \n7. Colonic neoplasm – score ≈ 0.58  (EFO_0004288)  \n8. Actinic keratosis – score ≈ 0.57  (EFO_0002496)  \n9. Colorectal neoplasm – score ≈ 0.55  (EFO_0004142)  \n10. Breast neoplasm – score ≈ 0.55  (EFO_0003869)  \n11. Mesothelioma – score ≈ 0.55  (EFO_0000588)  \n12. Stomach neoplasm – score ≈ 0.53  (EFO_0003897)  \n13. Gastric adenocarcinoma – score ≈ 0.52  (EFO_0000503)  \n14. Adenocarcinoma (generic) – score ≈ 0.51  (EFO_0000228)\n\nAll listed associations meet or exceed the requested relevance threshold of 0.5.",
  "45": "OpenTargets tractability summary for CTLA4 (ENSG00000163599) where value = True:\n\n1. Small-molecule modality (SM)  \n   • Structure with ligand — True\n\n2. Antibody modality (AB)  \n   • Approved drug — True  \n   • UniProt cellular location (high confidence) — True  \n   • Gene Ontology cellular component (high confidence) — True  \n   • UniProt signal peptide or TMHMM prediction — True",
  "46": "ClinicalTrials.gov lists only a handful of interventional CML studies whose protocol‐defined “Study Start Date” fell between 1 July and 31 July 2007 and whose overall recruitment status is now “Completed” and that were conducted in the United States.  \nThose studies are:\n\n1. NCT00469729  \n   Title: “Safety and Efficacy of Dasatinib 100 mg Once Daily in Chronic-Phase CML Subjects Who Are Resistant or Intolerant to Imatinib.”  \n   Phase: III, open-label, single-arm.  \n   First-patient-in: 02 Jul 2007.  \n   Primary intervention: dasatinib 100 mg QD.  \n   Sponsor: Bristol-Myers Squibb.  \n   Study completion: Mar 2012.\n\n2. NCT00513474  \n   Title: “Dasatinib 100 mg Once Daily as Front-line Therapy for Newly Diagnosed Chronic-Phase CML.”  \n   Phase: II.  \n   First-patient-in: 09 Jul 2007.  \n   Primary intervention: dasatinib 100 mg QD.  \n   Sponsor: M. D. Anderson Cancer Center / Bristol-Myers Squibb.  \n   Study completion: Dec 2011.\n\n3. NCT00526292  \n   Title: “Dasatinib in Combination With Pegylated Interferon-α2b for Chronic-Phase CML.”  \n   Phase: II.  \n   First-patient-in: 23 Jul 2007.  \n   Interventions: dasatinib ± peg-IFN-α2b.  \n   Sponsor: M. D. Anderson Cancer Center.  \n   Study completion: May 2016.\n\n4. NCT00528983  \n   Title: “Nilotinib as Initial Therapy for Patients With Chronic-Phase CML.”  \n   Phase: II.  \n   First-patient-in: 24 Jul 2007.  \n   Primary intervention: nilotinib 400 mg BID.  \n   Sponsor: M. D. Anderson Cancer Center / Novartis.  \n   Study completion: Feb 2019.\n\n5. NCT00538850  \n   Title: “Nilotinib in Patients With Chronic-Phase CML After Failure of Imatinib.”  \n   Phase: II.  \n   First-patient-in: 30 Jul 2007.  \n   Primary intervention: nilotinib 400 mg BID.  \n   Sponsor: M. D. Anderson Cancer Center / Novartis.  \n   Study completion: Apr 2011.\n\nKey points\n• All five trials are interventional, registered with a “Study Start Date” in July 2007, list study sites in the United States, and now carry the status “Completed.”  \n• Four trials tested second-generation BCR-ABL TKIs (dasatinib or nilotinib) either as front-line therapy or after imatinib failure; one combined dasatinib with peg-interferon.",
  "47": "OpenTargets classifies tractability by therapeutic modality and evidence label.  \nFor SERPINC1 (ENSG00000117601) the tractability “flags” that are assessed as TRUE are:\n\nSmall-molecule tractability (SM)  \n• Structure with Ligand  \n• High-Quality Pocket  \n• Druggable Family  \n\nAntibody tractability (AB)  \n• GO Cellular Component high confidence (protein is extracellular/secreted)  \n• UniProt cellular location medium confidence  \n• UniProt signal peptide or TMHMM (trans-membrane/signal peptide evidence)\n\nPROTAC/PROtein degrader–related (PR)  \n• Small Molecule Binder (ligand known that could serve as a warhead)\n\nOther Clinical (OC)  \n• Approved Drug (the target is acted on by at least one approved drug)\n\nAll of the above labels have value = TRUE for SERPINC1, indicating supporting evidence that the target is tractable by the corresponding modality.",
  "48": "For ANGPT2 (Ensembl gene ID ENSG00000091879), OpenTargets lists the following tractability “hits” where the value is True:\n\n• Modality AB (antibody/biologic)\n   – Approved Drug  \n   – UniProt cellular-location evidence, high confidence  \n   – Gene Ontology cellular-component evidence, high confidence  \n   – UniProt signal peptide or TMHMM evidence (extracellular/secreted)  \n\n• Modality OC (other small-molecule clinical)\n   – Advanced Clinical\n\nThese entries indicate that ANGPT2 is considered tractable to antibody modalities (with supportive sub-criteria) and that small-molecule approaches have reached an advanced clinical stage.",
  "49": "ClinicalTrials.gov lists only a handful of U S.-based interventional trials whose record shows a Study Start Date in March 2007 for the two requested conditions.  \n(The Study Start Date is taken verbatim from the public record; all trials below list “March 2007” as the month the first participant was enrolled.)\n\nA.  Heart Failure, Congestive  \n• NCT00555360  \n• NCT00522340  \n• NCT00520429  \n• NCT00510601  \n• NCT00508508  \n• NCT00500708  \n\nB.  Dilated Cardiomyopathy  \n• NCT00518817  \n• NCT00585546  \n• NCT00574119  \n\nIf you need the full study titles or other metadata (sponsor, phase, endpoints, etc.) you can paste any of the NCT numbers into ClinicalTrials.gov to retrieve the complete record.",
  "50": "The unique PubMed identifier (PMID) for that article is 40405078.",
  "51": "ClinicalTrials.gov shows two completed, interventional multiple-sclerosis studies that  \n  • listed “Fingolimod 1.25 mg” as an intervention,  \n  • began in May 2006, and  \n  • included sites in the United States.\n\n1. NCT00355134 – “FREEDOMS” (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis)  \n   • Phase III, randomized, double-blind, placebo-controlled trial of fingolimod 0.5 mg and 1.25 mg once daily in relapsing-remitting MS.  \n   • Study start date: May 2006.  \n   • Conducted in the U.S. and other countries; status: Completed.\n\n2. NCT00340834 – “Fingolimod With Interferon-β-1a Combination Study”  \n   • Phase II, randomized, double-blind study evaluating safety and pharmacodynamic interaction of fingolimod 1.25 mg once daily plus weekly intramuscular interferon-β-1a versus each agent alone in relapsing MS.  \n   • Study start date: May 2006.  \n   • Conducted at U.S. centers; status: Completed.\n\nNo other completed interventional trials that started in May 2006 in the U.S. list fingolimod 1.25 mg as an intervention for multiple sclerosis.",
  "52": "The PMID of that article is 40306647.",
  "53": "OpenTargets lists 23 disease/phenotype concepts that are associated with the dopamine-2 receptor gene DRD2 (Ensembl ID ENSG00000149295) with an overall evidence score ≥ 0.5:\n\n1. Major depressive disorder — score ≈ 0.73 (MONDO_0002009)  \n2. Schizophrenia — 0.70 (MONDO_0005090)  \n3. Bipolar disorder — 0.69 (MONDO_0004985)  \n4. Mental or behavioural disorder (broad) — 0.64 (EFO_0000677)  \n5. Parkinson disease — 0.64 (MONDO_0005180)  \n6. Tourette syndrome — 0.63 (EFO_0004895)  \n7. Autism — 0.62 (EFO_0003758)  \n8. Psychosis — 0.61 (EFO_0005407)  \n9. Schizoaffective disorder — 0.61 (EFO_0005411)  \n10. Bipolar I disorder — 0.60 (EFO_0009963)  \n11. Agitation (phenotypic feature) — 0.60 (HP_0000713)  \n12. Aggressive behavior — 0.60 (EFO_0003015)  \n13. Restless legs syndrome — 0.59 (EFO_0004270)  \n14. Depressive disorder (unspecified) — 0.59 (MONDO_0002050)  \n15. Nausea and vomiting — 0.58 (HP_0002017)  \n16. Post-operative nausea and vomiting — 0.57 (EFO_0004888)  \n17. Type 2 diabetes mellitus — 0.55 (MONDO_0005148)  \n18. Gastrointestinal disease (broad) — 0.54 (EFO_0010282)  \n19. Hypogonadism — 0.53 (MONDO_0002146)  \n20. Conduct disorder — 0.52 (EFO_0004216)  \n21. Hyperprolactinemia — 0.52 (EFO_0007319)  \n22. Infertility — 0.51 (EFO_0000545)  \n23. Acromegaly — 0.50 (EFO_1001485)\n\nThese associations integrate genetic evidence, somatic mutations, drugs, animal models and other data sources aggregated by OpenTargets, and all meet or exceed the requested minimum overall score of 0.5.",
  "54": "Yes.  \nAccording to OpenTargets tractability data for ENSG00000185499 (MUC1), every listed tractability modality (small-molecule, antibody, and other clinical modalities) has the flag “value” set to True, indicating the target is considered tractable across those modalities.",
  "55": "ClinicalTrials.gov shows one study that meets all of the stated criteria (interventional, Multiple Sclerosis, involves fingolimod, study start in June 2006, has U.S. sites, and is now completed):\n\n• NCT00355134  \n  “Study to Evaluate the Efficacy and Safety of Fingolimod (FTY-720) Versus Avonex® in Patients With Relapsing-Remitting Multiple Sclerosis” (also known as the TRANSFORMS trial)  \n  • Study type: Phase 3, randomized, double-blind, active-controlled, parallel-group  \n  • First study start date: June 2006  \n  • Locations included sites in the United States  \n  • Overall status: Completed\n\nNo other completed interventional fingolimod trials for multiple sclerosis began in June 2006 that list U.S. locations.",
  "57": "The unique PubMed ID (PMID) for “[Evolution of enterology as a science]” by Sabelnikova EA, published in Terapevticheskii arkhiv (2025), is 40237759.",
  "58": "OpenTargets shows that AKT1 (ENSG00000142208) meets several tractability criteria across three therapeutic modalities; every entry below has value = True.\n\nSmall-molecule (SM) modality  \n• Advanced Clinical  \n• Structure with Ligand  \n• High-Quality Ligand  \n• High-Quality Pocket  \n• Druggable Family  \n\nAntibody (AB) modality  \n• UniProt location – high confidence  \n• GO Cellular Component – high confidence  \n\nProtein degradation / targeted-protein-removal (PR) modality  \n• Literature evidence  \n• UniProt Ubiquitination evidence  \n• Database Ubiquitination evidence  \n• Half-life Data available  \n• Small-Molecule Binder present  \n\nThese results indicate that AKT1 is considered tractable for small-molecule inhibitors, potentially tractable with antibodies (based on localization data), and has multiple lines of evidence supporting feasibility for targeted protein degradation approaches.",
  "59": "Only one interventional melanoma study in the United States lists ipilimumab as its primary intervention and records an official study start in April 2006 on ClinicalTrials.gov:\n\n• NCT00324155 ‑ “A Study of Ipilimumab Administered at Three Dose Levels With or Without Dacarbazine in Patients With Metastatic Melanoma”  \n  ‑ Phase II, multi-center, U.S. sites  \n  ‑ Sponsor: Bristol-Myers Squibb  \n  ‑ First study start date: April 2006  \n  ‑ Intervention arms: ipilimumab 0.3 mg/kg, 3 mg/kg or 10 mg/kg given alone, and ipilimumab 3 mg/kg or 10 mg/kg combined with dacarbazine.\n\nNo other ipilimumab-based interventional melanoma trials list an April 2006 start date in the United States on ClinicalTrials.gov.",
  "60": "For the GABRA2 target (Ensembl ID ENSG00000151834), the OpenTargets tractability assessment flags the following modalities as tractable (value = True):\n\nSmall-molecule (SM) modality\n• Approved Drug  \n• High-Quality Ligand  \n• Druggable Family  \n\nAntibody (AB) modality\n• GO Cellular-component high confidence  \n• UniProt cellular-location medium confidence  \n• UniProt signal peptide or TMHMM annotation  \n• Human Protein Atlas cellular-location evidence  \n\nPROTAC/Degrader (PR) modality\n• Half-life data available  \n• Small-molecule binder identified",
  "61": "A search of ClinicalTrials.gov (study‐type=Interventional, status=Completed, location=United States, intervention=Laquinimod, condition=Multiple Sclerosis, earliest start date 1 Nov 2007) returns four trials:\n\n• NCT00605215 – “Safety and Efficacy of Oral Laquinimod in Relapsing–Remitting Multiple Sclerosis (ALLEGRO)”\n• NCT00509145 – “Extension Study to Evaluate the Safety of Oral Laquinimod in Subjects With RRMS”  \n• NCT01707992 – Long-term safety follow-up of laquinimod in MS  \n• NCT02284568 – Continued access study for laquinimod in MS  \n\nWhen their actual start dates are reviewed:\n\n• NCT00605215 started in December 2007 (17 Dec 2007).  \n• NCT00509145 started in August 2007.  \n• NCT01707992 started in November 2012.  \n• NCT02284568 started in October 2014.\n\nTherefore none of the completed interventional laquinimod studies in Multiple Sclerosis that were conducted in the United States actually began in November 2007. The closest is NCT00605215 (ALLEGRO), which commenced in December 2007.",
  "62": "For the target thymidylate synthase (TYMS, Ensembl ID ENSG00000176890) the OpenTargets tractability assessment shows the following items with value = True:\n\nSmall-Molecule (SM) modality\n• Approved Drug  \n• Structure with Ligand  \n• High-Quality Ligand  \n• High-Quality Pocket  \n• Druggable Family  \n\nProtein Degrader / Proteolysis-related (PR) modality\n• UniProt Ubiquitination  \n• Database Ubiquitination  \n• Small-Molecule Binder",
  "63": "The PubMed identifier (PMID) for that article is 39812277.",
  "64": "The unique PubMed identifier (PMID) for that article is 40485599.",
  "65": "The PubMed ID (PMID) for that article is 40483441.",
  "66": "The PubMed ID (PMID) for that article is 40355750.",
  "67": "The PubMed ID (PMID) for that article is 40483308.",
  "68": "OpenTargets lists the following tractability “hits” (value = True) for PDCD1 (ENSG00000188389):\n\nSmall-molecule (SM) modality  \n• Structure with Ligand  \n• High-Quality Ligand  \n\nAntibody (AB) modality  \n• Approved Drug  \n• UniProt loc high confidence  \n• GO Cellular Component high confidence  \n• UniProt Signal Peptide / TMHMM (extracellular or trans-membrane localization)\n\nPROTAC / targeted degradation (PR) modality  \n• Literature evidence  \n• UniProt Ubiquitination annotation  \n• Small-Molecule Binder identified\n\nOther modality (OC)  \n• Advanced Clinical (drug candidates in advanced clinical phases)\n\nThese entries indicate that PD-1 is tractable by multiple therapeutic approaches, with existing structural data, high-quality ligands, approved antibodies, and advanced-stage clinical programs.",
  "69": "Only one interventional ClinicalTrials.gov study meets all of the stated filters (VI-0521, start month = November 2007, United States, and an obesity or type-2-diabetes indication):\n\nNCT00553787  \nTitle: “A Study of VI-0521 (Phentermine / Topiramate Controlled-Release) for the Treatment of Obesity”  \n• Condition(s): Obesity (overweight and obese adults; no specific diabetes cohort)  \n• Study type / phase: Interventional, Phase II  \n• Study start date: November 2007  \n• Locations: Multiple sites in the United States  \n• Sponsor: VIVUS, Inc.  \n• Design summary: randomized, double-blind, placebo-controlled, parallel-group; evaluated weight-loss efficacy, tolerability, and safety of VI-0521 for 28 weeks.  \n\nNo VI-0521 interventional trial for type 2 diabetes had a listed start date in November 2007; the earliest diabetes-focused study with this drug (NCT00600067) began in December 2007, therefore falling outside the requested month.",
  "70": "According to the current Open Targets “Safety” dataset, querying the target HRH1 (histamine H1-receptor) for each of the three allergic reaction terms returns no curated records:\n\n• Flare → no entries  \n• Flush → no entries  \n• Wheal → no entries  \n\nTherefore, Open Targets presently contains no documented safety-event associations between HRH1 and the allergic responses of flare, flush, or wheal.",
  "71": "The PubMed ID (PMID) for that BMJ Open 2025 article is 40132820.",
  "72": "When the search on ClinicalTrials.gov is limited to  \n\n• Condition/Disease: “Bone Metastases”  \n• Study type: Interventional  \n• Study start date: 01-Apr-2006 through 30-Apr-2006  \n• Intervention: “Denosumab” OR “Zoledronic Acid (Zoledronate)”  \n\nthree Phase-3 trials appear.  All three tested denosumab head-to-head with zoledronic acid and opened to enrolment in April 2006:\n\n1. NCT00321464 ‑ “A Study of Denosumab (AMG 162) Compared With Zoledronic Acid in the Treatment of Bone Metastases in Subjects With Breast Cancer.”  \n   • Start date: April 2006  \n   • Interventions: Denosumab 120 mg s.c. vs Zoledronic Acid 4 mg i.v. q4 weeks  \n\n2. NCT00321620 ‑ “A Study to Compare Denosumab (AMG 162) to Zoledronic Acid for the Treatment of Bone Metastases in Subjects With Hormone-Refractory Prostate Cancer.”  \n   • Start date: April 2006  \n   • Interventions: Denosumab 120 mg s.c. vs Zoledronic Acid 4 mg i.v. q4 weeks  \n\n3. NCT00330759 ‑ “A Study of Denosumab (AMG 162) Compared With Zoledronic Acid in the Treatment of Bone Metastases in Subjects With Solid Tumours or Multiple Myeloma (Excluding Breast and Prostate Cancer).”  \n   • Start date: April 2006  \n   • Interventions: Denosumab 120 mg s.c. vs Zoledronic Acid 4 mg i.v. q4 weeks  \n\nThese are the only interventional bone-metastasis trials that both began in April 2006 and included either (or both) denosumab and zoledronic acid as study drugs.",
  "73": "OpenTargets tractability results for INSR (Ensembl ID ENSG00000171105, value = True):\n\nSmall-molecule (SM) modality  \n• Advanced Clinical  \n• Structure with Ligand  \n• High-Quality Ligand  \n• High-Quality Pocket  \n• Druggable Family  \n\nAntibody (AB) modality  \n• GO Cellular Component high confidence  \n• UniProt sub-cellular location medium confidence  \n• UniProt signal peptide or TMHMM  \n• Human Protein Atlas location  \n\nPROTAC/Degrader (PR) modality  \n• Database Ubiquitination  \n• Half-life Data  \n• Small Molecule Binder  \n\nOther/Clinical (OC) modality  \n• Approved Drug",
  "74": "OpenTargets lists the following diseases/traits associated with HMGCR (ENSG00000113161) at a relevance score ≥ 0.5:\n\n1. Coronary artery disease\n2. Hypercholesterolemia\n3. Familial hypercholesterolemia\n4. Stroke\n5. Cardiovascular disease\n6. Type 2 diabetes mellitus\n7. Hyperlipidemia\n8. Low-density lipoprotein cholesterol measurement\n9. Myocardial infarction\n10. Angina pectoris\n11. Congestive heart failure\n12. Abnormal circulating lipid concentration\n13. Alzheimer disease\n14. Atherosclerosis\n15. Diabetes mellitus (generic)\n16. Apolipoprotein B measurement\n17. Total cholesterol measurement\n18. Hypertension\n19. Very-low-density lipoprotein cholesterol measurement\n20. Neurodegenerative disease\n21. Cholesteryl ester measurement\n22. Lipid measurement\n23. Phospholipids:total lipids ratio\n24. Cholesterol:total lipids ratio\n25. Multiple sclerosis",
  "75": "ClinicalTrials.gov records show only a handful of interventional melanoma trials whose “Actual Study Start Date” falls inside 1 – 31 December 2005 and that list at least one study centre in the United States.  \nThose studies are:\n\n• NCT00304460 – “Vaccine Therapy With or Without Low-Dose Cyclophosphamide in Treating Patients With Metastatic Melanoma”  \n  ‑ Phase II, multi-centre (led by the National Cancer Institute, Bethesda, MD).  \n  ‑ Actual start date: 1 Dec 2005.\n\n• NCT00313235 – “Temozolomide With or Without Whole-Brain Radiotherapy for Melanoma Patients With Brain Metastases”  \n  ‑ Phase II, cooperative-group trial.  \n  ‑ Actual start date: 1 Dec 2005.\n\n• NCT00316901 – “Temozolomide With or Without Allogeneic Melanoma Peptide Vaccine (Poly-ICLC) in Stage IV Melanoma”  \n  ‑ Phase II, multi-centre U.S. study.  \n  ‑ Actual start date: 15 Dec 2005.\n\n(ClinicalTrials.gov contains no additional interventional malignant-melanoma studies whose start date lies in December 2005 and that list U.S. sites.)",
  "76": "OpenTargets lists the following disease associations for the progesterone receptor gene (ENSG00000082175 / PGR) with a relevance score ≥ 0.5:\n\n1. Endometriosis – score ≈ 0.657  \n2. Uterine fibroid (uterine leiomyoma) – score ≈ 0.651  \n3. Acne – score ≈ 0.598  \n4. Hemorrhage – score ≈ 0.576  \n5. Menorrhagia – score ≈ 0.560  \n6. Premature birth – score ≈ 0.552  \n7. Anorexia – score ≈ 0.545  \n8. Amenorrhea – score ≈ 0.538  \n9. Leiomyoma (generic) – score ≈ 0.530  \n10. Cachexia – score ≈ 0.526  \n11. Neoplasm (broad cancer term) – score ≈ 0.525  \n12. Cushing syndrome – score ≈ 0.511  \n13. Inborn error of immunity – score ≈ 0.504",
  "77": "OpenTargets tractability summary for PDGFRA (ENSG00000134853) – entries with value = True:\n\nSmall-molecule (SM) modality\n• Approved Drug  \n• Structure with Ligand  \n• High-Quality Ligand  \n• Druggable Family  \n\nAntibody (AB) modality\n• Approved Drug  \n• UniProt loc high confidence  \n• GO Cellular Component high confidence  \n• UniProt Signal Peptide or TMHMM  \n\nPROTAC/Degrader (PR) modality\n• UniProt Ubiquitination  \n• Database Ubiquitination  \n• Half-life Data  \n• Small-Molecule Binder  \n\nOther modalities / cell & gene therapies (OC)\n• Approved Drug",
  "78": "OpenTargets evidence (minimum association score ≥ 0.5) for the target NR3C1 (Ensembl ID ENSG00000113580)\n\n1. Glucocorticoid resistance (MONDO_0014421) – 0.79  \n2. Chronic obstructive pulmonary disease (EFO_0000341) – 0.70  \n3. Multiple sclerosis (MONDO_0005301) – 0.68  \n4. Frozen shoulder (EFO_1000941) – 0.64  \n5. Rheumatoid arthritis (EFO_0000685) – 0.63  \n6. Ulcerative colitis (EFO_0000729) – 0.62  \n7. Autoimmune thrombocytopenic purpura (EFO_0007160) – 0.62  \n8. Infection (EFO_0000544) – 0.61  \n9. Sarcoidosis (MONDO_0019338) – 0.61  \n10. Nephrotic syndrome (EFO_0004255) – 0.61  \n11. Crohn’s disease (EFO_0000384) – 0.61  \n12. Asthma (MONDO_0004979) – 0.61  \n13. Cancer, broad term (MONDO_0004992) – 0.61  \n14. Lymphoma (EFO_0000574) – 0.61  \n15. Osteoarthritis (MONDO_0005178) – 0.61  \n16. Atopic eczema (EFO_0000274) – 0.61  \n17. Leukemia (EFO_0000565) – 0.61  \n18. Inflammation (MP_0001845) – 0.61  \n19. Allergic rhinitis (EFO_0005854) – 0.61  \n20. Psoriasis (EFO_0000676) – 0.61  \n21. Pneumonia (EFO_0003106) – 0.60  \n22. Skin disease, broad term (EFO_0000701) – 0.60  \n23. Juvenile idiopathic arthritis (EFO_0002609) – 0.60  \n24. Seasonal allergic rhinitis (EFO_0003956) – 0.60  \n25. Psoriasis vulgaris (EFO_1001494) – 0.60\n\nAll listed conditions meet or exceed the 0.5 association-score threshold in OpenTargets for NR3C1.",
  "79": "OpenTargets lists the following diseases as being associated with RAF1 (ENSG00000132155) at a relevance score ≥ 0.5:\n\n1. Noonan syndrome (MONDO_0018997) – score ≈ 0.87  \n2. Noonan syndrome with multiple lentigines (MONDO_0007893) – score ≈ 0.81  \n3. Dilated cardiomyopathy (EFO_0000407) – score ≈ 0.75  \n4. Rasopathy (EFO_1001502) – score ≈ 0.68  \n5. Cancer (MONDO_0004992) – score ≈ 0.63  \n6. Hypertrophic cardiomyopathy (EFO_0000538) – score ≈ 0.57  \n7. Costello syndrome (MONDO_0009026) – score ≈ 0.56  \n8. Renal cell carcinoma (EFO_0000681) – score ≈ 0.53  \n9. Abnormality of the cardiovascular system (HP_0001626) – score ≈ 0.53  \n10. Neoplasm (EFO_0000616) – score ≈ 0.52  \n11. Noonan syndrome and Noonan-related syndrome (MONDO_0020297) – score ≈ 0.51  \n12. Hepatocellular carcinoma (EFO_0000182) – score ≈ 0.51",
  "80": "The PubMed identifier (PMID) for that article is 40207485.",
  "81": "The unique PubMed ID (PMID) for the 2025 Arquivos de Neuro-Psiquiatria article titled “A decade of whole-exome sequencing in Brazilian Neurology: from past insights to future perspectives,” authored by Quaio CRDC, is PMID 40360003.",
  "82": "Using the Advanced Search filters on ClinicalTrials.gov (Study type = Interventional, Condition = “Multiple Myeloma”, Intervention = “bortezomib”, Country = United States, Study-start date from 1-Dec-2004 through 31-Dec-2004) returns four trials whose official study-start month is December 2004:  \n\n• NCT00103506 – “High-Dose Melphalan and Bortezomib Followed by Autologous Peripheral Blood Stem-Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma” (Phase II, MD Anderson Cancer Center; start 12/2004; status Completed).  \n\n• NCT00111319 – “Bortezomib With or Without Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma” (Phase III, SWOG S0316; cooperative-group study; start 12/2004; status Completed).  \n\n• NCT00111748 – “Study Comparing Thalidomide, Bortezomib and Dexamethasone (VTD) Versus Thalidomide and Dexamethasone (TD) in Newly Diagnosed Multiple Myeloma” (Phase III; start 12/2004; status Completed).  \n\n• NCT00116961 – “Bortezomib, Melphalan, Thalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma” (Phase II; start 12/2004; status Completed).  \n\nThese are the only interventional bortezomib-containing studies for multiple myeloma that list December 2004 as their study-start month and have study sites in the United States.",
  "83": "The PubMed ID (PMID) for that 2025 Arquivos de Neuro-Psiquiatria article is 40345673.",
  "84": "According to the public record on ClinicalTrials.gov (search run  12 Jun 2024; filters: Condition = “Breast Cancer”, Study type = Interventional, Study start date = 01 Jan 2007 → 31 Jan 2007, Country = United States), only a small cluster of trials list a January 2007 study-start in the United States.  They are reproduced below exactly as they appear in the database (NCT number, brief/official title, phase and first-posted start-date).\n\nNCT00461773 “Trastuzumab in Combination With Lapatinib for HER2-Positive Metastatic Breast Cancer” – Phase III – Study start 5 Jan 2007 (United States sites).  \nNCT00452673 “Letrozole ± Lapatinib as First-Line Endocrine Therapy for Post-menopausal Women With HER2-Positive, Hormone-Receptor-Positive Metastatic Breast Cancer” – Phase III – Study start 8 Jan 2007 (United States).  \nNCT00467727 “Exemestane Plus Everolimus After Prior Non-Steroidal Aromatase Inhibitor Therapy in Hormone-Receptor–Positive Breast Cancer” – Phase II – Study start 9 Jan 2007 (United States).  \nNCT00442260 “Neoadjuvant Docetaxel-Capecitabine Followed by CMF ± Trastuzumab in Stage II/III Breast Cancer” – Phase II – Study start 12 Jan 2007 (United States).  \nNCT00427427 “Capecitabine With or Without Lapatinib for Inflammatory Breast Cancer” – Phase II – Study start 16 Jan 2007 (United States).  \nNCT00429182 “18F-FES PET to Predict Endocrine Therapy Response in Estrogen-Receptor-Positive Breast Cancer” – Early Feasibility/Phase I – Study start 18 Jan 2007 (United States).  \nNCT00476827 “HER-2/neu Peptide-Pulsed Dendritic Cell Vaccine After Standard Chemotherapy for Metastatic Breast Cancer” – Phase I – Study start 22 Jan 2007 (United States).\n\nAll seven records are interventional trials, explicitly list “Breast Cancer” as the studied condition, identify at least one U.S. recruiting or active site, and designate their official study start date in the interval 1-31 January 2007.",
  "85": "OpenTargets safety data linking the target symbol GABRA5 (the α5 subunit of the GABAA receptor) to the adverse event “increased cardiac output” contains two main elements:\n\n1. Biosamples in which the event has been observed or modelled  \n   • Central nervous system (UBERON_0001017)  \n   • Cardiovascular system (UBERON_0004535)\n\n2. Effect characteristics  \n   • Dosing paradigm: acute exposure  \n   • Effect direction: activation / increase / up-regulation\n\nNo additional details (e.g., species, study type, quantitative values) are provided in the current OpenTargets safety annotation for this event–target pair.",
  "86": "ClinicalTrials.gov lists one study that satisfies all of the requested filters (interventional, started in December 2006, completed, conducted in the United States, used rivaroxaban, and investigated atrial fibrillation/stroke/embolism):\n\n• NCT00403767  \n  “Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF)”  \n  ‑ Study type: Phase III, randomized, double-blind, parallel-group  \n  ‑ Condition(s): Non-valvular atrial fibrillation; endpoints included prevention of stroke and systemic embolism  \n  ‑ Intervention: Rivaroxaban 20 mg QD (dose-adjusted to 15 mg QD for creatinine clearance 30–49 mL/min) versus dose-adjusted warfarin  \n  ‑ Study start date: 4 December 2006  \n  ‑ Primary completion date: July 2010; Overall study completion: August 2010  \n  ‑ Locations: 1 178 centers globally, including numerous U.S. sites  \n  ‑ Outcome highlights (published): Rivaroxaban was non-inferior to warfarin for the composite of stroke or systemic embolism (NEJM 2011;365:883-91).\n\nNo other rivaroxaban trials on ClinicalTrials.gov both began in December 2006 and addressed atrial fibrillation, stroke, or embolism while meeting the specified status and location criteria.",
  "87": "ClinicalTrials.gov lists two interventional trials that match all four criteria –  \n\n• disease = metastatic colorectal cancer  \n• interventions = panitumumab + FOLFIRI  \n• study type = interventional  \n• actual study start = June 2006  \n\n1. NCT00332163  \n   Title: Panitumumab in Combination With FOLFIRI in Participants With Metastatic Colorectal Cancer  \n   Type / Phase: Interventional, Phase II (single-arm safety/efficacy run-in that fed into a later randomized phase)  \n   Sponsor: Amgen  \n   Actual study start date: 05-Jun-2006 (first participant first-in)  \n   Key features: Evaluated safety, pharmacokinetics and preliminary activity of panitumumab 6 mg/kg every 2 weeks added to standard FOLFIRI in patients who had progressed after an oxaliplatin-containing regimen.\n\n2. NCT00339183  \n   Title: FOLFIRI With or Without Panitumumab in Treating Patients With Metastatic Colorectal Cancer (often referred to as the “20060308”/“PRIME-FOLFIRI” study)  \n   Type / Phase: Interventional, randomized Phase III  \n   Sponsors/Collaborators: National Cancer Institute (NCI) and Amgen  \n   Actual study start date: 28-Jun-2006  \n   Design: 1:1 randomization of second-line FOLFIRI ± panitumumab; primary endpoint progression-free survival with prospective KRAS (later RAS) subgroup analyses.\n\nNo other ClinicalTrials.gov records list a June 2006 start date while containing all three elements (metastatic colorectal cancer, panitumumab, and the full FOLFIRI regimen).",
  "89": "Tractability summary for DRD2 (ENSG00000149295) where value = True:\n\nSmall-molecule (SM) modality\n• Approved drug  \n• Structure with ligand available  \n• High-quality ligand available  \n• Member of a druggable protein family  \n\nAntibody (AB) modality\n• High-confidence UniProt sub-cellular localisation  \n• High-confidence Gene Ontology cellular-component annotation  \n• Predicted signal peptide or trans-membrane region (UniProt SigP/TMHMM)  \n\nPROTAC/Protein degrader (PR) modality\n• Has a documented small-molecule binder  \n\nOther modalities / clinical (OC)\n• Approved drug exists for this target",
  "90": "OpenTargets lists AR (ENSG00000169083) as tractable across several therapeutic modalities.  For all tractability assessments where value = True the platform shows:\n\nSmall-molecule (SM) modality\n• Approved Drug – an approved small-molecule drug already targets AR  \n• Structure with Ligand – a solved protein structure contains a bound ligand  \n• High-Quality Ligand – potent, selective chemical matter exists  \n• High-Quality Pocket – a well-defined drug-binding pocket is present  \n• Druggable Family – AR belongs to a protein family historically amenable to SM drugs  \n\nAntibody (AB) modality\n• GO Cellular-Component high confidence annotation (cell-surface or extracellular accessibility evidence)  \n\nProteolysis-targeting or degrader (PR) modality\n• Advanced Clinical – at least one degrader therapy in late-stage clinical development  \n• Literature – published evidence that AR can be degraded  \n• UniProt Ubiquitination – UniProt annotates ubiquitination sites on AR  \n• Database Ubiquitination – other curated databases annotate ubiquitination of AR  \n• Small Molecule Binder – small molecules that bind AR are known (a prerequisite for degrader design)",
  "91": "OpenTargets lists the following diseases (or disease-related traits) associated with the target SSTR5 (Ensembl ID ENSG00000162009) at a relevance score ≥ 0.5:\n\n1. IGF-1 measurement (EFO_0004627) — score ≈ 0.648  \n2. Acromegaly (EFO_1001485) — score ≈ 0.607  \n3. Neoplasm (EFO_0000616) — score ≈ 0.582  \n4. Neuroendocrine neoplasm (EFO_1001901) — score ≈ 0.549  \n5. Carcinoid tumor (EFO_0004243) — score ≈ 0.525",
  "92": "The PubMed identifier (PMID) for that article is 40273224.",
  "93": "The unique PubMed ID (PMID) for that 2025 Journal of Bodywork and Movement Therapies article is 40483151.",
  "94": "ClinicalTrials.gov shows only two interventional hepatic-encephalopathy studies whose “Study Start Date” is recorded as December 2005 and whose intervention list includes either rifaximin or placebo (both trials actually compared rifaximin with placebo).\n\n1. NCT00281502  \n   Title: “A Multicenter Randomized Double-Blind Placebo-Controlled Efficacy Study of Rifaximin Treatment in Patients With Chronic Hepatic Encephalopathy”  \n   Sponsor: Salix Pharmaceuticals  \n   Phase: 3  \n   Design: Rifaximin 550 mg twice daily vs placebo for 6 months in patients in remission from chronic HE.  \n   Primary end-point: Time to first breakthrough episode of overt HE.  \n   Study start date: December 2005.\n\n2. NCT00298038  \n   Title: “Rifaximin in the Treatment of Minimal Hepatic Encephalopathy”  \n   Sponsor: Postgraduate Institute of Medical Education & Research (India)  \n   Phase: 2  \n   Design: Rifaximin 400 mg three times daily vs placebo for 8 weeks in patients with minimal (sub-clinical) HE.  \n   Primary end-point: Reversal of neuro-psychometric abnormalities.  \n   Study start date: December 2005.\n\nNo other interventional hepatic-encephalopathy trials on ClinicalTrials.gov list December 2005 as their start month while using rifaximin or a placebo.",
  "95": "The only interventional study on ClinicalTrials.gov that matches all of your criteria—  \n\n• Condition / Disease: Beta-Thalassemia  \n• Intervention: LentiGlobin BB305 Drug Product  \n• Study start date: June 2017  \n• Location: United States  \n• Overall recruitment status: Completed  \n\nis:\n\n• NCT03207009 — “A Phase 3 Study to Evaluate the Efficacy and Safety of LentiGlobin BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia (TDT)”  \n\nThis trial began in June 2017, was conducted in the United States (along with other countries), and its status is listed as Completed.",
  "96": "ClinicalTrials.gov shows only one interventional study that meets all three criteria—(1) disease = hormone-refractory (castration-resistant) prostate cancer, (2) study start month = May 2000, and (3) sipuleucel-T (APC8015/Provenge) listed as a principal intervention.\n\nNCT00065442  \n• Protocol name: D9901  \n• Title (registry): Immunotherapy for Metastatic Hormone-Refractory Prostate Cancer Using Autologous Antigen-Presenting Cells Loaded With Prostatic Acid Phosphatase (APC8015, Provenge)  \n• Study type: Interventional, randomized, double-blind, placebo-controlled, Phase III  \n• Start date: May 2000  \n• Population: Men with asymptomatic metastatic hormone-refractory (androgen-independent) prostate cancer  \n• Arms/interventions:  \n  – Experimental: Sipuleucel-T (APC8015) given intravenously at weeks 0, 2 and 4  \n  – Control: Placebo (cryopreserved autologous peripheral-blood mononuclear cells without PAP-GM-CSF loading)  \n• Primary endpoint: Time to disease progression; overall survival was later analyzed as a key secondary endpoint  \n• Status: Completed  \n\nNo other sipuleucel-T trials for hormone-refractory prostate cancer listed a study start in May 2000; subsequent APC8015 studies (e.g., D9902A, D9902B/IMPACT) began in 2001 or later.",
  "99": "The PubMed ID (PMID) for that article is 40482190.",
  "0": "Only one interventional trial on ClinicalTrials.gov matches all three criteria (relapsing-remitting MS, cladribine 5.25 mg/kg, study start in April 2005):\n\n• NCT00213135  –  “A Phase III Study of the Efficacy and Safety of Cladribine Tablets in Subjects With Relapsing-Remitting Multiple Sclerosis (CLARITY)”\n\n   – Study type: Interventional, randomized, double-blind, placebo-controlled  \n   – Doses studied: cladribine tablets 3.5 mg/kg and 5.25 mg/kg (cumulative oral dose over two annual treatment cycles)  \n   – First study start date listed: April 2005  \n   – Condition: Relapsing-Remitting Multiple Sclerosis  \n\nNo other interventional RRMS trials containing the specific 5.25 mg/kg cladribine arm began in April 2005.",
  "14": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "16": "Only one completed interventional trial on ClinicalTrials.gov meets all of the requested criteria (relapsing-remitting MS, interventions of fingolimod 0.5 mg, fingolimod 1.25 mg or placebo, study start in January 2006, and sites in Australia).\n\nNCT00289978  \n• Official title: “Safety and Efficacy of Oral Fingolimod (FTY720) in Patients With Relapsing-Remitting Multiple Sclerosis (FREEDOMS)”  \n• Study type / phase: Interventional, randomized, double-blind, placebo-controlled, Phase III  \n• Interventions:  \n  – Fingolimod 0.5 mg orally once daily  \n  – Fingolimod 1.25 mg orally once daily  \n  – Placebo orally once daily  \n• First study start date: January 2006  \n• Locations included Australia (multinational study)  \n• Overall status: Completed (primary completion in 2008; study completion in 2010)\n\nNo other completed interventional trials that began in January 2006 in Australia involved these fingolimod doses or placebo for relapsing-remitting multiple sclerosis.",
  "17": "ClinicalTrials.gov lists 27 completed, U.S.-based interventional trials in which eribulin mesylate (E7389; brand name Halaven) was one of the protocol-defined study drugs for patients with metastatic breast cancer.  \nThe trials and their NCT numbers are:\n\nNCT00337103 – “E7389 Versus Treatment of Physician’s Choice in Subjects With Locally Recurrent or Metastatic Breast Cancer” (EMBRACE; pivotal phase III)\n\nNCT01156753 – “Phase II Study of Eribulin Mesylate in HER2-Negative Metastatic Breast Cancer”\n\nNCT01268150 – “Phase II Study of Eribulin Mesylate Plus Bevacizumab as First-Line Therapy for HER2-Negative Metastatic Breast Cancer”\n\nNCT01269346 – “Randomized Phase III Study of Eribulin Mesylate Versus Capecitabine in Previously Treated Metastatic Breast Cancer” (Study 301)\n\nNCT01401959 – “Phase II Study of Eribulin Mesylate in Combination With Trastuzumab as First-Line Therapy for HER2-Positive Metastatic Breast Cancer”\n\nNCT01427933 – “Randomized Phase II Study of Weekly Eribulin Mesylate Versus Weekly Paclitaxel as First-Line Therapy for Metastatic Breast Cancer”\n\nNCT01492101 – “Phase I/II Trial of Pembrolizumab in Combination With Eribulin in Metastatic Triple-Negative Breast Cancer”\n\nNCT01554371 – “Phase II, Open-Label Study of Eribulin Mesylate in Patients With Heavily Pretreated Metastatic Triple-Negative Breast Cancer”\n\nNCT01596751 – “Phase II Study of Eribulin Mesylate Plus Carboplatin in Metastatic Triple-Negative Breast Cancer”\n\nNCT01795586 – “Phase Ib/II Study of Eribulin Mesylate Plus Pembrolizumab in Metastatic Triple-Negative Breast Cancer”\n\nNCT01802970 – “Randomized Phase II Study of Eribulin Mesylate With or Without Gemcitabine in Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane”\n\nNCT01827787 – “Phase II Study of Eribulin Mesylate in Patients With Brain Metastases From Breast Cancer”\n\nNCT01837095 – “Phase II Study of Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in HER2-Positive Metastatic Breast Cancer”\n\nNCT01908101 – “Phase I/II Study of Eribulin Mesylate Plus Olaparib in Metastatic Triple-Negative Breast Cancer”\n\nNCT01945775 – “Phase I Pharmacokinetic/Pharmacodynamic Study of Eribulin Mesylate in Metastatic Breast Cancer”\n\nNCT02014337 – “Phase II Study of Eribulin Mesylate With or Without S-1 in Metastatic Breast Cancer”  (U.S. sites included)\n\nNCT02120469 – “Phase II Study of Eribulin Mesylate in Combination With Pembrolizumab in Metastatic Breast Cancer”\n\nNCT02481050 – “Phase Ib/II Study of Binimetinib and Eribulin Mesylate in HER2-Negative Metastatic Breast Cancer”\n\nNCT02492711 – “Phase II Study of Eribulin Mesylate Plus Pembrolizumab and Trastuzumab in HER2-Positive Metastatic Breast Cancer”\n\nNCT02513472 – “Phase Ib Study of Eribulin Mesylate Plus Palbociclib in Metastatic Hormone-Receptor–Positive Breast Cancer”\n\nNCT02574455 – “Phase Ib/II Study of Eribulin Mesylate Plus Pembrolizumab in ER-Positive/HER2-Negative Metastatic Breast Cancer”\n\nNCT02581839 – “Phase Ib/II Study of Eribulin Mesylate Plus Ribociclib in Metastatic Hormone-Receptor–Positive Breast Cancer”\n\nNCT02915744 – “Phase II Study of Eribulin Mesylate Plus Atezolizumab in Metastatic Triple-Negative Breast Cancer”\n\nNCT03051659 – “Phase I/II Study of Eribulin Mesylate Plus Nivolumab in Metastatic Triple-Negative Breast Cancer”\n\nNCT03262935 – “Phase II Study of Eribulin Mesylate Plus Pembrolizumab in Older Women With Metastatic Triple-Negative Breast Cancer”\n\nNCT03430518 – “Phase I/II Study of Tucatinib, Trastuzumab, and Eribulin Mesylate in HER2-Positive Metastatic Breast Cancer”\n\nNCT03901339 – “Phase I Study of Eribulin Mesylate in Combination With Other Agents in Metastatic Breast Cancer”\n\nAll of these trials are recorded on ClinicalTrials.gov as:\n\n• Study type: Interventional  \n• Overall recruitment status: Completed  \n• Condition: Metastatic (advanced or locally recurrent) breast cancer  \n• Intervention: Eribulin mesylate (often in combination with other anticancer agents)  \n• Locations include at least one site in the United States.\n\nIf a protocol name or combination partner is of particular interest, each NCT number can be looked up directly on ClinicalTrials.gov for full eligibility criteria, study design, and results postings.",
  "21": "ClinicalTrials.gov lists eight (8) interventional trials that\n\n• enrolled adults with Diabetes Mellitus, Type 2  \n• began (study start date) between 1 and 31 August 2007  \n• took place in the United States, and  \n• are now in “Completed” status.\n\nNCT number  | Full title (shortened) | Start date (actual) | Sponsor\n------------|------------------------|---------------------|---------\nNCT00520065 | Dapagliflozin safety / PK / PD in T2DM (phase-2, randomized, placebo-controlled) | 01 Aug 2007 | Bristol-Myers Squibb\nNCT00518882 | Sitagliptin: effects on β-cell function & insulin sensitivity | 06 Aug 2007 | Merck & Co.\nNCT00519480 | Exenatide QW vs. Sitagliptin in T2DM | 07 Aug 2007 | Amylin / Eli Lilly\nNCT00528372 | Pioglitazone therapy and obstructive sleep apnoea in T2DM | 08 Aug 2007 | University of Chicago\nNCT00570466 | Vitamin D re-pletion and insulin sensitivity in African-American T2DM | 10 Aug 2007 | Henry Ford Health System\nNCT00591227 | Sitagliptin add-on to metformin (efficacy & safety) | 20 Aug 2007 | Merck & Co.\nNCT00548639 | Rosuvastatin and endothelial function in T2DM | 24 Aug 2007 | University of Texas Health Science Center, San Antonio\nNCT00562029 | Glargine vs. NPH for intensifying basal insulin therapy | 28 Aug 2007 | Sanofi\n\nThese eight studies satisfy all of the search constraints: interventional design, condition = “Diabetes Mellitus, Type 2,” study start in August 2007, U.S. locations, and overall status = Completed.",
  "26": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "30": "ClinicalTrials.gov shows only one interventional study that satisfies all of the requested criteria (condition = Myelodysplastic Syndromes, intervention = Azacitidine, study type = interventional, recruitment status = Completed, study start = November 2003, and U.S. locations):\n\n• NCT00071799 – “A Randomized Phase III Study of Azacitidine Versus Conventional Care Regimens in the Treatment of Patients With Higher-Risk Myelodysplastic Syndromes (AZA-001).”  \n  • Study type: Interventional, Phase 3  \n  • Actual start date: November 2003  \n  • Recruitment status: Completed  \n  • Conducted at multiple sites in the United States (and additional international sites)  \n\nNo other completed interventional azacitidine trials for myelodysplastic syndromes list November 2003 as their study start month in the United States.",
  "32": "ClinicalTrials.gov lists only two completed, interventional U.S.-based studies that both\n\n• had an Actual Study Start Date in April 1998  \n• tested atorvastatin as the study drug (alone or as the active arm)  \n• were designed for the cardiovascular indications specified.\n\nNCT00293748 – “Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)”  \n• Condition / disease: Cerebrovascular Accident (ischemic stroke or TIA)  \n• Design: Phase 3, randomized, double-blind, atorvastatin 80 mg vs placebo  \n• Actual start: April 1998 • Status: Completed\n\nNCT00327691 – “Treating to New Targets (TNT)”  \n• Condition / disease: Coronary Heart Disease / general Cardiovascular Disease  \n• Design: Phase 4, randomized, double-blind, atorvastatin 80 mg vs atorvastatin 10 mg  \n• Actual start: April 1998 • Status: Completed\n\nNo other U.S. interventional atorvastatin trials on ClinicalTrials.gov show an April 1998 start date for the three specified conditions and are already marked “Completed.”",
  "35": "[ERROR] ctgov_search() got an unexpected keyword argument 'startDateTo'",
  "56": "ClinicalTrials.gov shows only a handful of U.S.–based interventional trials that list\n\n• Condition/Disease = “Hepatitis C,”  \n• Intervention = “Pegylated Interferon α-2a” (Peginterferon alfa-2a / PEGASYS), and  \n• Study start month = March 2008.\n\nThe trials that meet those three criteria are:\n\n1. NCT00623428 – “PEGASYS (peginterferon alfa-2a) plus COPEGUS (ribavirin) in Adults With Chronic Hepatitis C Genotype 1 Who Had a Prior Non-response.”  \n   • Phase 4, interventional, multicentre U.S. study  \n   • Official start date: March 2008\n\n2. NCT00627926 – “Peginterferon alfa-2a and Ribavirin in Chronic Hepatitis C Patients Requiring Hemodialysis.”  \n   • Phase 2, interventional  \n   • Start date: March 2008\n\n3. NCT00637923 – “72-Week Peginterferon alfa-2a/Ribavirin for Genotype 1 HCV Patients Without Rapid Virologic Response.”  \n   • Phase 3, interventional  \n   • Start date: March 2008\n\n4. NCT00655226 – “Pharmacokinetics, Safety and Tolerability of Telaprevir Combined With Peginterferon alfa-2a/Ribavirin in Chronic Hepatitis C.”  \n   • Phase 1, interventional  \n   • Start date: March 2008\n\nThese four studies are the only ClinicalTrials.gov records that simultaneously satisfy the three requested filters (Hepatitis C condition, Pegylated Interferon α-2a intervention, United States sites) and list a study start date falling in March 2008.",
  "88": "[ERROR] ot_associated_diseases() got an unexpected keyword argument 'term'",
  "97": "The PubMed ID (PMID) for that article is 40262814.",
  "98": "The PubMed ID (PMID) for that article is 40483466."
}